144 related articles for article (PubMed ID: 2881449)
21. Regionally selective changes in neurotransmitter receptors in the brain of the 5-HT1B knockout mouse.
Ase AR; Reader TA; Hen R; Descarries L
J Chem Neuroanat; 2008 Jul; 35(4):356-63. PubMed ID: 18406571
[TBL] [Abstract][Full Text] [Related]
22. Potential nondopaminergic drugs for Parkinson's disease.
Silverdale MA; Fox SH; Crossman AR; Brotchie JM
Adv Neurol; 2003; 91():273-91. PubMed ID: 12442686
[No Abstract] [Full Text] [Related]
23. Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata.
Seeman P; Guan HC; Van Tol HH; Niznik HB
Synapse; 1993 Aug; 14(4):247-53. PubMed ID: 8248849
[TBL] [Abstract][Full Text] [Related]
24. Modulation of phencyclidine receptor sensitivity.
Quirion R; Pert CB
NIDA Res Monogr; 1983 Apr; 43():217-23. PubMed ID: 6308454
[No Abstract] [Full Text] [Related]
25. Brain receptor changes in Parkinson's disease in relation to the disease process and treatment.
Rinne UK; Rinne JO; Rinne JK; Laakso K; Laihinen A; Lönnberg P
J Neural Transm Suppl; 1983; 18():279-86. PubMed ID: 6308149
[TBL] [Abstract][Full Text] [Related]
26. PET and SPECT functional imaging in Parkinson's disease.
Antonini A; DeNotaris R
Sleep Med; 2004 Mar; 5(2):201-6. PubMed ID: 15033144
[TBL] [Abstract][Full Text] [Related]
27. Anatomical and biochemical basis of the extrapyramidal disorders.
Gauthier S; Sourkes TL
Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):595-9. PubMed ID: 6131493
[TBL] [Abstract][Full Text] [Related]
28. [How can PET scan be used in Parkinson disease?].
Tedroff J
Nord Med; 1998 Feb; 113(2):48, 52. PubMed ID: 9497616
[TBL] [Abstract][Full Text] [Related]
29. Dopamine D2 receptor density in parkinsonian brain is constant for duration of disease, age, and duration of L-dopa therapy.
Guttman M; Seeman P
Adv Neurol; 1987; 45():51-7. PubMed ID: 2950731
[No Abstract] [Full Text] [Related]
30. Addiction: brain mechanisms and their treatment implications.
Nutt DJ
Lancet; 1996 Jan; 347(8993):31-6. PubMed ID: 8531549
[No Abstract] [Full Text] [Related]
31. Neurotoxicity and the mechanisms of cell death in Parkinson's disease.
Schapira AH
Adv Neurol; 1996; 69():161-5. PubMed ID: 8615125
[No Abstract] [Full Text] [Related]
32. Measurement of neurotransmitter receptors by positron emission tomography: focus on the opiate receptor.
Frost JJ
NIDA Res Monogr; 1986; 74():15-24. PubMed ID: 2827031
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of motor complications in treatment of Parkinson's disease.
Kumar A; Huang Z; de la Fuente-Fernández R
Adv Neurol; 2003; 91():193-201. PubMed ID: 12442678
[No Abstract] [Full Text] [Related]
34. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias.
Piccini P; Weeks RA; Brooks DJ
Ann Neurol; 1997 Nov; 42(5):720-6. PubMed ID: 9392571
[TBL] [Abstract][Full Text] [Related]
35. Stereoselective neuroimaging in vivo.
Smith DF; Jakobsen S
Eur Neuropsychopharmacol; 2007 Jul; 17(8):507-22. PubMed ID: 17368004
[TBL] [Abstract][Full Text] [Related]
36. Functional integration of neural grafts in Parkinson's disease.
Barker RA; Dunnett SB
Nat Neurosci; 1999 Dec; 2(12):1047-8. PubMed ID: 10570477
[TBL] [Abstract][Full Text] [Related]
37. Nicotinic and muscarinic cholinergic receptors in Alzheimer's disease and related disorders.
Whitehouse PJ; Kellar KJ
J Neural Transm Suppl; 1987; 24():175-82. PubMed ID: 2960781
[TBL] [Abstract][Full Text] [Related]
38. [Receptors in positron emission tomography].
Suehiro M
No To Shinkei; 1982 Sep; 34(9):853-62. PubMed ID: 6291562
[No Abstract] [Full Text] [Related]
39. Mechanisms of Parkinson's disease.
Br Med J; 1978 Apr; 1(6117):872-3. PubMed ID: 25109
[No Abstract] [Full Text] [Related]
40. Parkinson's disease: neurotransmitter and neurotoxin receptors and their genes.
Uhl GR
Eur Neurol; 1990; 30 Suppl 1():21-30. PubMed ID: 1968832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
